No Data
No Data
Express News | Scholar Rock Initiates Phase 2 EMBRAZE Trial Of Apitegromab In Obesity And Announces New Preclinical Data Showing SRK-439 Is 'More Potent Than an Anti-ActRII Antibody in Maintaining Lean Mass in Diet-induced Obesity (DIO) Mice'
Express News | Scholar Rock Holding Corp - Primary Data From Embraze Will Inform Scholar Rock's Development of Srk-439 Towards an Anticipated Ind Filing in 2025
Express News | Scholar Rock Holding Corp - Primary Data From Embraze Are Expected in Mid-2025
Express News | Scholar Rock Announces Initiation of Phase 2 Embraze Trial of Apitegromab in Obesity and New Preclinical Data Supporting Srk-439 in Obesity
Scholar Rock to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic dis
Does Scholar Rock Holding (NASDAQ:SRRK) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
No Data